glp-1 receptor agonist blue cross blue shield Drops Coverage of Obesity Drugs GLP‑1 Coverage Cuts: How Insurer

Author Contributions Kayla Parsons: writing original draft (lead), writing review and editing (equal)

Over the past two decades, the discovery of the incretin hormone glucagon-like peptide-1 (GLP-1) and the subsequent success of blockbuster diabetes medications targeting GLP-1 signaling transformed the translational research field

OCULAR ADVERSE EFFECTS Other cancers Recent investigations have highlighted the association between various neoplasms, such as thyroid, breast, and cholangiocarcinoma, and GLP-1 RAs [105-107]

Dose adjustments, slower titration [dose increase] schedules, hydration strategies, nutrition counseling, and other symptom-management approaches can often help improve tolerability

Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the national institutes of health all of us cohort